Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
CAMBRIDGE, Mass., Feb. 17, 2016 -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, February 24, 2016 at 8:30 AM ET to report its fourth quarter and full year 2015 financial results and discuss recent business updates.
The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 49865237. A replay of the webcast will be available on Sage’s website approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics [email protected] 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC [email protected] 585-387-9248
